OptiCept Technologies (OPTI) investor relations material

Executive summary

• Q2 2026 marked a major transformation, including a cost-reduction program, organizational restructuring, and the transition of the PEF business to FPS, resulting in improved operational cash flow and EBITDA by 67% year-over-year.

• The FPS commercialization agreement, effective April 2026, generated SEK 21.1 million in revenue from inventory sales and license fees, with no profit-sharing revenue recognized yet.

• Workforce reduced to 11 employees, two warehouses closed, and IT/consulting agreements optimized to lower the fixed-cost base.

• PlantTech segment advanced with successful trials in Indonesia and ongoing tests in South America; first commercial order for cuttings expected before year-end.

Financial highlights

• Q2 2026 net sales: SEK 23.3 million (Q2 2025: SEK 1.2 million); total revenue: SEK 25.9 million (Q2 2025: SEK 3.2 million).

• EBITDA improved to SEK -5.4 million (Q2 2025: SEK -16.5 million); operating income: SEK -15.7 million (Q2 2025: SEK -31.5 million).

• Net result for Q2: SEK -16.4 million (Q2 2025: SEK -32.0 million); earnings per share: SEK -0.19 (Q2 2025: SEK -0.51).

• Cash flow from operating activities: SEK 4.5 million (Q2 2025: SEK -10.1 million); period-end cash: SEK 3.6 million.

• Order intake for Q2 includes the full FPS agreement (approx. SEK 156 million in license value), inventory sale of SEK 14.4 million, and additional equipment order of SEK 0.9 million.

Outlook and guidance

• Positive EBITDA expected no later than H2 2026, supported by cost reductions and FPS agreement.

• First commercial PlantTech order for cuttings anticipated before end of 2026.

• Company dependent on converting SEK 11 million FPS loan maturing September 2026 or securing alternative financing within 12 months.